Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).

Open Label ◽

A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Case Medical Research ◽

10.31525/ct1-nct04115761 ◽

2019 ◽

Author(s):

Keyword(s):

Dendritic Cell ◽

Glioblastoma Multiforme ◽

Phase Ii ◽

Dendritic Cell Vaccination ◽

Efficacy And Safety ◽

Open Label ◽

Primary Glioblastoma ◽

Parallel Group Study ◽

Parallel Group

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-2-16 ◽

2014 ◽

Vol 2 (1) ◽

Cited By ~ 19

Author(s):

Paul LR Mitchell ◽

Michael A Quinn ◽

Peter T Grant ◽

David G Allen ◽

Thomas W Jobling ◽

...

Keyword(s):

Ovarian Cancer ◽

Dendritic Cell ◽

Epithelial Ovarian Cancer ◽

Phase 2 ◽

Advanced Epithelial Ovarian Cancer

Mucin 1 ◽

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

Journal for ImmunoTherapy of Cancer ◽

10.1186/s40425-016-0137-x ◽

2016 ◽

Vol 4 (1) ◽

Cited By ~ 10

Author(s):

H. J. Gray ◽

B. Benigno ◽

J. Berek ◽

J. Chang ◽

J. Mason ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Dendritic Cell ◽

Cell Therapy ◽

Cancer Patients ◽

Phase 2 ◽

Mucin 1 ◽

Phase 2 Trial ◽

Dendritic Cell Therapy ◽

Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.07.003 ◽

2021 ◽

Author(s):

David Cibula ◽

Lukas Rob ◽

Peter Mallmann ◽

Pawel Knapp ◽

Jaroslav Klat ◽

...

Keyword(s):

Ovarian Cancer ◽

Dendritic Cell ◽

Second Line ◽

Phase 2 ◽

Open Label ◽

Second Line Chemotherapy ◽

Platinum Sensitive ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: a randomized, open-label, phase I/II trial

Cancer Treatment and Research Communications ◽

10.1016/j.ctarc.2021.100427 ◽

2021 ◽

pp. 100427

Author(s):

Milada Zemanova ◽

Marketa Cernovska ◽

Libor Havel ◽

Tomas Bartek ◽

Sarka Lukesova ◽

...

Keyword(s):

Lung Cancer ◽

Dendritic Cell ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

Cancer Immunology Immunotherapy ◽

10.1007/s00262-012-1261-1 ◽

2012 ◽

Vol 61 (11) ◽

pp. 2033-2044 ◽

Cited By ~ 89

Author(s):

Hilko Ardon ◽

Stefaan W. Van Gool ◽

Tina Verschuere ◽

Wim Maes ◽

Steffen Fieuws ◽

...

Keyword(s):

Dendritic Cell ◽

Phase I ◽

Standard Of Care ◽

Newly Diagnosed ◽

Care Treatment ◽

Standard Of Care Treatment ◽

Newly Diagnosed Glioblastoma

Durvalumab, Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Targeted Radiotherapy in Metastatic Non-Small Cell Lung Cancer Refractory to Prior PD-1 Therapy: A Multicentre, Open-Label, Randomized, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3922682 ◽

2021 ◽

Author(s):

Jonathan D. Schoenfeld ◽

Anita Giobbie-Hurder ◽

Srinika Ranasinghe ◽

Katrina Z. Kao ◽

Ana Lako ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Low Dose ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Targeted Radiotherapy ◽

Phase 2 Trial ◽

An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3546 ◽

2021 ◽

pp. clincanres.3546.2020

Author(s):

Ning Li ◽

Hualei Bu ◽

Jihong Liu ◽

Jianqing Zhu ◽

Qi Zhou ◽

...

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Phase 2 ◽

Open Label ◽

Platinum Sensitive ◽

Phase 2 Study

O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)

Annals of Oncology ◽

10.1016/j.annonc.2020.04.064 ◽

2020 ◽

Vol 31 ◽

pp. 235

Author(s):

K. Yamaguchi ◽

Y. Bang ◽

S. Iwasa ◽

N. Sugimoto ◽

M. Ryu ◽

...

Keyword(s):

Gastroesophageal Junction ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Gastroesophageal Junction Adenocarcinoma ◽

O 11 ◽

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients

Frontiers in Immunology ◽

10.3389/fimmu.2019.01832 ◽

2019 ◽

Vol 10 ◽

Cited By ~ 9

Author(s):

Michal Bassani-Sternberg ◽

Antonia Digklia ◽

Florian Huber ◽

Dorothea Wagner ◽

Christine Sempoux ◽

...

Keyword(s):

Dendritic Cell ◽

Adjuvant Chemotherapy ◽

Pancreatic Adenocarcinoma ◽

Dendritic Cell Vaccine ◽

Standard Of Care ◽

Cell Vaccine ◽

Phase Ib ◽

Antigen Discovery